Comparison of Efficacy and Safety of the Domestic Nateglinide with Repaglinide on Type 2 Diabetes Mellitus-Multi-Centre, Double-Blind, Dummy, Randomised Clinical Trial

田浩明,李启富,王乃尊,吴桐,刘雅,倪宗瓒,喻红玲,李健薇,罗蓉,黎英荣,黄恋川,夏彦

DOI: https://doi.org/10.3969/j.issn.1672-2531.2004.07.004

2004-01-01

Abstract:Objective To evaluate efficacy and safety of domestic Nateglinide tablet in comparison with domestic Repaglinide in Type 2 diabeties. Method s A multi-centre, double-blind, dummy trial was conduct e d.Two hundred and thirty type 2 diabetic patients recuited from 5 clinical cent ers were randomly allocated into Group A (domestic Repaglinide, 1.0 mg tid, and Group B (domestic Nateglinide, 90 mg tid, .The trial consisted of a 4 weeksequilibrated period followed b y 12 weeks treatment course .Results Ninety s even percent of patients(223) completed the trial (110 in Group A and 113 in Gr oup B). The mean of fasting blood glucose (FBG) in both Group A and B was decre ased statistically ( P 0.000 1) after 2, 6 and 12 weeks durat ion. At week 12, the mean FBG in Group A and B was reduced by 1.68±1.81 mmol /L (17.27%) and 1.17±1.67 mmol/L (12.53%) respectively with statistically s ignificant difference between the two groups( P=0.017 7). The mean of 120 minutes postprandial blood glucose(PBG) also lowered markedly in 2, 6, and 12 weeks in both groups. At the end of therapy, PBG of 30, 60, 120 m inutes were reduced significantly, mean of 120 minutes PBG was reduced 3.95±3 .25 mmol/L (26.12%), and 3.81±3.05 mmol/L (26.22%) respectively in Group A and B , the differences in reduction between Group A and B had no statistical s ignificance (P=0.726 9). In Group A and B, the mean of Alc was reduced significantly after 12 weeks duration. At week 12, the mean of Alc in Group A and B was lowered by 1.21% and 0.68% respectively, with statistical di fference between the two groups (P0.002 3). Though fasti ng insulin level in both groups had no change after 12 weeks duration, the insul in level at 30, 60 and 120 min increased significantly in both groups ( P0.000 1). It suggested that both Nateglinide and Repaglinide promot ed insulin secretion in early phase with maximal value at 60 min in Repaglinide group and 30 min in Nateglinide group, respectively. The adverse reaction rate in Group A including hypoglycemic reaction, thrombocytopenia and recrudescence o f HBV was 4.5% when compared to only one case of thrombocytopenia in Group B (0 .87%). Conclusions Both domestic Nateglinide and Repaglinide have similar effect on reducing postprandial blood glucose, but Repaglinide has stronger effect on reducing FBG and A1c than Nateglinide. The r esults suggest that both domestic Nateglinide and Repaglinide are safe and gener ally well-tolerated in type 2 diabetic patients.